Management

Mr. Pucci joined ArQule as Chief Executive Officer and a member of the board of directors in June 2008 from Bayer A.G., where he served as Senior Vice President (SVP) in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Unit. Previously at Bayer, Mr. Pucci was concomitantly SVP of the Global Specialty Business Unit and President of North America Pharmaceutical Operations and a member of the Bayer Pharmaceuticals Global Management Committee. At Bayer, Mr. Pucci was involved in a broad range of activities related to the governance of Bayer global pharmaceutical operations. In his capacities as SVP of the Global Specialty Business unit he was responsible for leading the creation of Bayer’s Global Oncology franchise with the commercial launch of Nexavar® (sorafenib), an oral multiple kinase inhibitor approved for treatment of liver and kidney cancers. Subsequent to the acquisition of Schering A.G. by Bayer A.G., Mr. Pucci led the integration of the Bayer-Schering global oncology franchises. Mr. Pucci joined Bayer in 2001 as head of its Italian Pharmaceutical and Biologicals operations. Prior to Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. At Lilly, his responsibilities included operations, sales, marketing and strategic planning related to the therapeutic areas of CNS, endocrinology, anti-infectives and oncology. Mr. Pucci currently serves on the Board of Directors at NewLink Genetics Corporation and West Pharmaceutical Service Inc., positions he was appointed to in November 2015 and September 2016, respectively. In November 2011, Mr. Pucci was appointed to the Board of Directors of Dyax Corporation, where he served as an independent director, member of the audit committee and chairman of the governance and nomination committee until its acquisition by Shire plc in January 2016. In April 2013, he was appointed to the Board of Directors of Algeta ASA, a Norwegian public company focused on oncology and based in Oslo, Norway. At Algeta he served as an independent director and member of the audit committee until the acquisition of Algeta by Bayer A.G. in March 2014. Mr. Pucci holds an MBA from the University of Chicago Booth, is an Italian chartered accountant and a graduate in economics of the Universita Degli Studi Di Napoli Federico II in Naples, Italy.

Mr. Lawrence joined ArQule in April 2006 from Pod Holding Ltd., an international venture capital firm which he co-founded in 2001 and where he most recently served as general partner. He helped drive the strategic growth of that firm, including deal sourcing and structuring, syndication and business expansion activities and served as President of its US subsidiary. Mr. Lawrence served as lead partner on investment activities for a number of companies, including the cancer company, Pintex Pharmaceuticals. His public financing experience includes the initial public offering and numerous financings for America Online Inc. (AOL), as well as public financings for Biogen, Human Genome Sciences, Hybridon and many other companies. He worked on numerous mergers and acquisitions, including AOL/Time Warner, Roche/Compuchem, Steinway Piano, DEC/Intel, and Mitotix/GPC Biotech. Previously, Mr. Lawrence was an attorney and partner at Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., from 1991 to 2001. At Mintz Levin, he served as external corporate counsel to public and private companies, managed a transactional legal practice and provided strategic guidance to clients through periods of rapid growth and transformative corporate events. Mr. Lawrence worked at Gaston & Snow from 1989 to 1991 in the firm’s Corporate Law Department. He holds a Bachelor’s degree from Amherst College and a J.D. from Boston University School of Law.

Dr. Schwartz joined ArQule as Chief Medical Officer in July 2008 and in 2013 he took on the responsibility of head of research and development. Dr. Schwartz has more than a decade of experience in the pharmaceutical and biotechnology industries. Prior to joining ArQule, he was senior vice president, clinical and regulatory affairs, and chief medical officer at Ziopharm Oncology where he built and led the clinical, regulatory, and quality assurance departments with responsibilities for the development of new cancer drugs. Prior to Ziopharm, Dr. Schwartz held a number of positions at Bayer Healthcare. His experience in oncology encompassed the clinical development of novel cytostatic, cytotoxic and immunological agents. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA’s Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has also been responsible for U.S. clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry.

Dr. Schegerin joined ArQule in May 2018 as Senior Vice President, Head of Corporate Strategy, Finance and Communication from Citigroup where he served as a Healthcare Investment Banking Director. There, he was responsible for the sourcing, planning and execution of dozens of deals across biopharma globally, including M&A/Strategic Advisory and Debt and Equity offerings totaling more than $40bn. Prior to working at CitiGroup, Dr. Schegerin held healthcare investment banking positions at Merrill Lynch as Vice President and Goldman Sachs, where he began his banking career. Dr. Schegerin also served in multiple industry roles, first at Biogen in BD/Strategy, Clinical Development and Program Leadership where he led multiple programs, including aducanumab, and later at Sage Therapeutics where he was the Head of Program & Portfolio Management. Dr. Schegerin holds degrees from Tulane University and Harvard University. He received his M.D. from Dartmouth Medical School (Payson/Hampers Scholar) and M.B.A. from the Tuck School of Business at Dartmouth (Don Wilson III Scholar).

Dr. Hirani joined ArQule in February 2018 from ARIAD Pharmaceuticals, an oncology focused biotechnology company that was acquired by Takeda in 2017. In his capacity as Vice President of Drug Development at ARIAD, Dr. Hirani was involved in a broad range of activities related to the successful global clinical development of the therapeutic agents, ponatinib (Iclusig®) and brigatinib (Alunbrig®). From March 2002 to September 2005, Dr. Hirani was Vice President of Program Management at Transkaryotic Therapies where he had the overall responsibility for the clinical development of idursulfase (Elaprase®) for the treatment of Hunter syndrome. Prior to that and during his tenure at Dyax Corp., from October 1997 to March 2002, Dr. Hirani was instrumental with the initiation of the clinical development program of ecallantide (Kalbitor®) for the treatment of hereditary angioedema. Dr. Hirani began his career in the biopharmaceutical industry at Genzyme where he spearheaded its glycoprotein remodeling programs that resulted in the development of the biologics, alglucerase and imiglucerase (Ceredase®/Cerezyme®), for the treatment of Gaucher disease. Dr. Hirani received a B.Sc. (Honors) and a Ph.D. in biochemistry from the Queen Elizabeth College, University of London and conducted postdoctoral studies at the University of California San Diego and at The Scripps Research Institute, La Jolla.

Mr. Weiskopf joined ArQule in February 2007 as Vice President of Finance, Corporate Controller, and Treasurer and was promoted to Chief Financial Officer and Treasurer in May 2015. Prior to that, Mr. Weiskopf was Chief Financial Officer of Aware Inc. from 2004 until 2006 and Director of Finance at Lightbridge, Inc. from 2000 to 2004. He held a number of financial management positions of increasing responsibility at Digital/Compaq Computer Corporation for 19 years and began his career working at Ernst & Young LLP for five years. Mr. Weiskopf was also a part-time instructor in the Boston University M.B.A. program. Mr. Weiskopf is a Certified Public Accountant and holds a B.S.B.A. magna cum laude and M.S.B.A. in accounting from the University of Massachusetts at Amherst.

Paolo Pucci

Chief Executive Officer

Mr. Pucci joined ArQule as Chief Executive Officer and a member of the board of directors in June 2008 from Bayer A.G., where he served as Senior Vice President (SVP) in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Unit. Previously at Bayer, Mr. Pucci was concomitantly SVP of the Global Specialty Business Unit and President of North America Pharmaceutical Operations and a member of the Bayer Pharmaceuticals Global Management Committee. At Bayer, Mr. Pucci was involved in a broad range of activities related to the governance of Bayer global pharmaceutical operations. In his capacities as SVP of the Global Specialty Business unit he was responsible for leading the creation of Bayer’s Global Oncology franchise with the commercial launch of Nexavar® (sorafenib), an oral multiple kinase inhibitor approved for treatment of liver and kidney cancers. Subsequent to the acquisition of Schering A.G. by Bayer A.G., Mr. Pucci led the integration of the Bayer-Schering global oncology franchises. Mr. Pucci joined Bayer in 2001 as head of its Italian Pharmaceutical and Biologicals operations. Prior to Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. At Lilly, his responsibilities included operations, sales, marketing and strategic planning related to the therapeutic areas of CNS, endocrinology, anti-infectives and oncology. Mr. Pucci currently serves on the Board of Directors at NewLink Genetics Corporation and West Pharmaceutical Service Inc., positions he was appointed to in November 2015 and September 2016, respectively. In November 2011, Mr. Pucci was appointed to the Board of Directors of Dyax Corporation, where he served as an independent director, member of the audit committee and chairman of the governance and nomination committee until its acquisition by Shire plc in January 2016. In April 2013, he was appointed to the Board of Directors of Algeta ASA, a Norwegian public company focused on oncology and based in Oslo, Norway. At Algeta he served as an independent director and member of the audit committee until the acquisition of Algeta by Bayer A.G. in March 2014. Mr. Pucci holds an MBA from the University of Chicago Booth, is an Italian chartered accountant and a graduate in economics of the Universita Degli Studi Di Napoli Federico II in Naples, Italy.

Peter S. Lawrence

President and Chief Operating Officer

Mr. Lawrence joined ArQule in April 2006 from Pod Holding Ltd., an international venture capital firm which he co-founded in 2001 and where he most recently served as general partner. He helped drive the strategic growth of that firm, including deal sourcing and structuring, syndication and business expansion activities and served as President of its US subsidiary. Mr. Lawrence served as lead partner on investment activities for a number of companies, including the cancer company, Pintex Pharmaceuticals. His public financing experience includes the initial public offering and numerous financings for America Online Inc. (AOL), as well as public financings for Biogen, Human Genome Sciences, Hybridon and many other companies. He worked on numerous mergers and acquisitions, including AOL/Time Warner, Roche/Compuchem, Steinway Piano, DEC/Intel, and Mitotix/GPC Biotech. Previously, Mr. Lawrence was an attorney and partner at Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., from 1991 to 2001. At Mintz Levin, he served as external corporate counsel to public and private companies, managed a transactional legal practice and provided strategic guidance to clients through periods of rapid growth and transformative corporate events. Mr. Lawrence worked at Gaston & Snow from 1989 to 1991 in the firm’s Corporate Law Department. He holds a Bachelor’s degree from Amherst College and a J.D. from Boston University School of Law.

Marc Schegerin, MD, MBA

Senior Vice PresidentHead of Strategy, Finance and Communication

Dr. Schegerin joined ArQule in May 2018 as Senior Vice President, Head of Corporate Strategy, Finance and Communication from Citigroup where he served as a Healthcare Investment Banking Director. There, he was responsible for the sourcing, planning and execution of dozens of deals across biopharma globally, including M&A/Strategic Advisory and Debt and Equity offerings totaling more than $40bn. Prior to working at CitiGroup, Dr. Schegerin held healthcare investment banking positions at Merrill Lynch as Vice President and Goldman Sachs, where he began his banking career. Dr. Schegerin also served in multiple industry roles, first at Biogen in BD/Strategy, Clinical Development and Program Leadership where he led multiple programs, including aducanumab, and later at Sage Therapeutics where he was the Head of Program & Portfolio Management. Dr. Schegerin holds degrees from Tulane University and Harvard University. He received his M.D. from Dartmouth Medical School (Payson/Hampers Scholar) and M.B.A. from the Tuck School of Business at Dartmouth (Don Wilson III Scholar).

Brian Schwartz

Chief Medical Officer

Dr. Schwartz joined ArQule as Chief Medical Officer in July 2008 and in 2013 he took on the responsibility of head of research and development. Dr. Schwartz has more than a decade of experience in the pharmaceutical and biotechnology industries. Prior to joining ArQule, he was senior vice president, clinical and regulatory affairs, and chief medical officer at Ziopharm Oncology where he built and led the clinical, regulatory, and quality assurance departments with responsibilities for the development of new cancer drugs. Prior to Ziopharm, Dr. Schwartz held a number of positions at Bayer Healthcare. His experience in oncology encompassed the clinical development of novel cytostatic, cytotoxic and immunological agents. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA’s Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has also been responsible for U.S. clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry.

Robert J. Weiskopf

Chief Financial Officer

Mr. Weiskopf joined ArQule in February 2007 as Vice President of Finance, Corporate Controller, and Treasurer and was promoted to Chief Financial Officer and Treasurer in May 2015. Prior to that, Mr. Weiskopf was Chief Financial Officer of Aware Inc. from 2004 until 2006 and Director of Finance at Lightbridge, Inc. from 2000 to 2004. He held a number of financial management positions of increasing responsibility at Digital/Compaq Computer Corporation for 19 years and began his career working at Ernst & Young LLP for five years. Mr. Weiskopf was also a part-time instructor in the Boston University M.B.A. program. Mr. Weiskopf is a Certified Public Accountant and holds a B.S.B.A. magna cum laude and M.S.B.A. in accounting from the University of Massachusetts at Amherst.

Shirish Hirani, Ph.D.

Senior Vice President, Program Management and Product Planning

Dr. Hirani joined ArQule in February 2018 from ARIAD Pharmaceuticals, an oncology focused biotechnology company that was acquired by Takeda in 2017. In his capacity as Vice President of Drug Development at ARIAD, Dr. Hirani was involved in a broad range of activities related to the successful global clinical development of the therapeutic agents, ponatinib (Iclusig®) and brigatinib (Alunbrig®). From March 2002 to September 2005, Dr. Hirani was Vice President of Program Management at Transkaryotic Therapies where he had the overall responsibility for the clinical development of idursulfase (Elaprase®) for the treatment of Hunter syndrome. Prior to that and during his tenure at Dyax Corp., from October 1997 to March 2002, Dr. Hirani was instrumental with the initiation of the clinical development program of ecallantide (Kalbitor®) for the treatment of hereditary angioedema. Dr. Hirani began his career in the biopharmaceutical industry at Genzyme where he spearheaded its glycoprotein remodeling programs that resulted in the development of the biologics, alglucerase and imiglucerase (Ceredase®/Cerezyme®), for the treatment of Gaucher disease. Dr. Hirani received a B.Sc. (Honors) and a Ph.D. in biochemistry from the Queen Elizabeth College, University of London and conducted postdoctoral studies at the University of California San Diego and at The Scripps Research Institute, La Jolla.